Consensus Statement of the Canadian MS Clinics Network on: The Use of Disease Modifying Agents in Multiple Sclerosis

Joël Oger; Mark Freedman

doi:10.1017/S0317167100000378

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Crossref Citations

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Comi, Giancarlo 2000. Why treat early multiple sclerosis patients?. Current Opinion in Neurology, Vol. 13, Issue. 3, p. 235.

MacLean, Heather J. and Freedman, Mark S. 2001. Immunologic therapy for relapsing-remitting multiple sclerosis. Current Neurology and Neuroscience Reports, Vol. 1, Issue. 3, p. 277.

Rieckmann, P. 2001. Multiple Sklerose. p. 109.

Zettl, U. K. Dressler, D. and Guthoff, R. 2001. Multiple Sklerose. p. 135.

Arnold, Anthony C. and Lee, Andrew G. 2001. Systemic Disease and Neuro-ophthalmology: Annual Update 2000 (Part I). Journal of Neuro-ophthalmology, Vol. 21, Issue. 1, p. 46.

Goodin, Douglas S. 2001. Interferon-?? Therapy in Multiple Sclerosis. Drugs, Vol. 61, Issue. 12, p. 1693.

Chofflon, Michel and Ben-Amor, Ali-Frederic 2002. Long-term benefits of early and high doses of interferon β-1a treatment in relapsing–remitting multiple sclerosis. Clinical Neurology and Neurosurgery, Vol. 104, Issue. 3, p. 244.

Freedman, M S Blumhardt, L D Brochet, B Comi, G Noseworthy, J H Sandberg-Wollheim, M and Sørensen, P Soelberg 2002. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Multiple Sclerosis Journal, Vol. 8, Issue. 1, p. 19.

Jeffery, Douglas Bashir, Khurram Buchwald, Linda Coyle, Patricia Freedman, Mark Markowitz, Clyde Rammohan, Kottil Reder, Tony Sharief, Mo and Wolinsky, Jerry 2002. Optimizing immunomodulatory therapy for MS patients: an integrated management model. Journal of the Neurological Sciences, Vol. 201, Issue. 1-2, p. 89.

Coyle, PK and Hartung, H-P. 2002. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Multiple Sclerosis Journal, Vol. 8, Issue. 1_suppl, p. 2.

Calabresi, Peter A. 2002. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology, Vol. 58, Issue. 8_suppl_4,

Coyle, P K and Hartung, H-P 2002. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Multiple Sclerosis Journal, Vol. 8, Issue. 1, p. 2.

Flachenecker, Peter and Rieckmann, Peter 2003. Early Intervention in Multiple Sclerosis. Drugs, Vol. 63, Issue. 15, p. 1525.

Johnson, K P Brooks, B R Ford, C C Goodman, A D Lisak, R P Myers, L W Pruitt, A A Rizzo, M A Rose, J W Weiner, L P and Wolinsky, J S 2003. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Multiple Sclerosis Journal, Vol. 9, Issue. 6, p. 585.

Comi, G. and Moiola, L. 2004. Early Indicators Early Treatments Neuroprotection in Multiple Sclerosis. p. 1.

Rieckmann, P. and Toyka, K. V. 2004. Escalating immunotherapy of multiple sclerosis. Journal of Neurology, Vol. 251, Issue. 11, p. 1329.

2004. Treatment optimization in multiple sclerosis: report of an international consensus meeting. European Journal of Neurology, Vol. 11, Issue. 1, p. 43.

Freedman, Mark S. Patry, David G. Grand'Maison, François Myles, Mary Lou Paty, Donald W. and Selchen, Daniel H. 2004. Treatment Optimization in Multiple Sclerosis. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, Vol. 31, Issue. 2, p. 157.

Johnson, K. P. Ford, C. C. Lisak, R. P. and Wolinsky, J. S. 2005. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurologica Scandinavica, Vol. 111, Issue. 1, p. 42.

Flachenecker, Peter 2005. Intramuscular Interferon-??-1a: In Patients at High Risk of Developing Clinically Definite Multiple Sclerosis. CNS Drugs, Vol. 19, Issue. 1, p. 63.

Download full list

Article contents

Consensus Statement of the Canadian MS Clinics Network on: The Use of Disease Modifying Agents in Multiple Sclerosis

Abstract

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests